CM-338 (Anti-MASP2 Antibody)

M-338 is a human recombinant monoclonal antibody (mAb) targeting MASP2 (Mannan-binding lectin serine protease 2). CM-338 can be used in IgA nephropathy research. MASP2 (Mannan-binding lectin serine protease 2) is a serine protease involved in the activation of the lectin pathway (LP) of the complement system. The recognition of mannose residues present in pathogens by MBL triggers the activation of MASP2, and the cleavage of components C4 and C2. Activation of LP is one of the main contributions in IgAN (immunoglobulin A nephropathy), a disorder that can lead to end-stage renal damage. Therapies targeting MASP2 are being developed, such as a first -in-class N-acetylgalactosamine-conjugated small interfering siRNA. FB7013, one such therapeutic, has show to inhibit LP activation during IgAN. Another strategy involves the use of recombinant antibodies, such as Narsoplimab, also known as Yartemlea, approved for the treatment of infections.